135 related articles for article (PubMed ID: 30579590)
1. Societal willingness to pay to avoid mortality and morbidity from Clostridioides difficile and carbapenem-resistant Enterobacteriaceae infections in the United States.
Sertkaya A; Wong HH; Ertis DH; Jessup A
Am J Infect Control; 2019 May; 47(5):521-526. PubMed ID: 30579590
[TBL] [Abstract][Full Text] [Related]
2. Fast and expensive (PCR) or cheap and slow (culture)? A mathematical modelling study to explore screening for carbapenem resistance in UK hospitals.
Knight GM; Dyakova E; Mookerjee S; Davies F; Brannigan ET; Otter JA; Holmes AH
BMC Med; 2018 Aug; 16(1):141. PubMed ID: 30111322
[TBL] [Abstract][Full Text] [Related]
3. Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States.
Bartsch SM; McKinnell JA; Mueller LE; Miller LG; Gohil SK; Huang SS; Lee BY
Clin Microbiol Infect; 2017 Jan; 23(1):48.e9-48.e16. PubMed ID: 27642178
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network.
Zhang Y; Wang Q; Yin Y; Chen H; Jin L; Gu B; Xie L; Yang C; Ma X; Li H; Li W; Zhang X; Liao K; Man S; Wang S; Wen H; Li B; Guo Z; Tian J; Pei F; Liu L; Zhang L; Zou C; Hu T; Cai J; Yang H; Huang J; Jia X; Huang W; Cao B; Wang H
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203488
[TBL] [Abstract][Full Text] [Related]
5. Factors associated to prevalence and treatment of carbapenem-resistant Enterobacteriaceae infections: a seven years retrospective study in three tertiary care hospitals.
Pang F; Jia XQ; Zhao QG; Zhang Y
Ann Clin Microbiol Antimicrob; 2018 Mar; 17(1):13. PubMed ID: 29571291
[TBL] [Abstract][Full Text] [Related]
6. Differences in the rate of carbapenem-resistant Enterobacteriaceae colonisation or Clostridium difficile infection following frontline treatment with tigecycline vs. meropenem for intra-abdominal infections.
Bartoletti M; Tedeschi S; Pascale R; Raumer L; Maraolo AE; Palmiero G; Tumietto F; Cristini F; Ambretti S; Giannella M; Lewis RE; Viale P
Int J Antimicrob Agents; 2018 Mar; 51(3):516-521. PubMed ID: 29410250
[TBL] [Abstract][Full Text] [Related]
7. The role of therapy with aminoglycoside in the outcomes of kidney transplant recipients infected with polymyxin- and carbapenem-resistant Enterobacteriaceae.
Freire MP; de Oliveira Garcia D; Cury AP; Francisco GR; Dos Santos NF; Spadão F; Bueno MFC; Camargo CH; de Paula FJ; Rossi F; Nahas WC; David-Neto E; Pierrotti LC
Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):755-765. PubMed ID: 30680569
[TBL] [Abstract][Full Text] [Related]
8. Rapid Increase in Prevalence of Carbapenem-Resistant Enterobacteriaceae (CRE) and Emergence of Colistin Resistance Gene
Li Y; Sun QL; Shen Y; Zhang Y; Yang JW; Shu LB; Zhou HW; Wang Y; Wang B; Zhang R; Wang S; Shen Z
J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29386265
[TBL] [Abstract][Full Text] [Related]
9. Asymptomatic rectal colonization with carbapenem-resistant Enterobacteriaceae and Clostridium difficile among residents of a long-term care facility in New York City.
Prasad N; Labaze G; Kopacz J; Chwa S; Platis D; Pan CX; Russo D; LaBombardi VJ; Osorio G; Pollack S; Kreiswirth BN; Chen L; Urban C; Segal-Maurer S
Am J Infect Control; 2016 May; 44(5):525-32. PubMed ID: 26796684
[TBL] [Abstract][Full Text] [Related]
10. Assessing the social cost and benefits of a national requirement establishing antibiotic stewardship programs to prevent
Scott RD; Slayton RB; Lessa FC; Baggs J; Culler SD; McDonald LC; Jernigan JA
Antimicrob Resist Infect Control; 2019; 8():17. PubMed ID: 30680153
[TBL] [Abstract][Full Text] [Related]
11. A Comprehensive Study of Costs Associated With Recurrent Clostridium difficile Infection.
Rodrigues R; Barber GE; Ananthakrishnan AN
Infect Control Hosp Epidemiol; 2017 Feb; 38(2):196-202. PubMed ID: 27817758
[TBL] [Abstract][Full Text] [Related]
12. Genetic Characterization of Carbapenem-Resistant Enterobacteriaceae and the Spread of Carbapenem-Resistant Klebsiella pneumonia ST340 at a University Hospital in Thailand.
Netikul T; Kiratisin P
PLoS One; 2015; 10(9):e0139116. PubMed ID: 26407326
[TBL] [Abstract][Full Text] [Related]
13. Mortality and Costs in Clostridium difficile Infection Among the Elderly in the United States.
Shorr AF; Zilberberg MD; Wang L; Baser O; Yu H
Infect Control Hosp Epidemiol; 2016 Nov; 37(11):1331-1336. PubMed ID: 27572289
[TBL] [Abstract][Full Text] [Related]
14. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis.
Zilberberg MD; Nathanson BH; Sulham K; Fan W; Shorr AF
BMC Infect Dis; 2017 Apr; 17(1):279. PubMed ID: 28415969
[TBL] [Abstract][Full Text] [Related]
15. Multicenter Study of the Risk Factors for Colonization or Infection with Carbapenem-Resistant Enterobacteriaceae in Children.
Chiotos K; Tamma PD; Flett KB; Naumann M; Karandikar MV; Bilker WB; Zaoutis T; Han JH
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971864
[TBL] [Abstract][Full Text] [Related]
16. How Should We Treat HAP/VAP Caused by Carbapenemase-Producing Enterobacteriaceae?
Bassetti M; Peghin M; Carnelutti A; Righi E
Semin Respir Crit Care Med; 2017 Jun; 38(3):301-310. PubMed ID: 28578554
[TBL] [Abstract][Full Text] [Related]
17. A systematic review of the epidemiology of carbapenem-resistant Enterobacteriaceae in the United States.
Livorsi DJ; Chorazy ML; Schweizer ML; Balkenende EC; Blevins AE; Nair R; Samore MH; Nelson RE; Khader K; Perencevich EN
Antimicrob Resist Infect Control; 2018; 7():55. PubMed ID: 29719718
[TBL] [Abstract][Full Text] [Related]
18. Risk factors and outcomes associated with the isolation of polymyxin B and carbapenem-resistant Enterobacteriaceae spp.: A case-control study.
Teo JQ; Chang CW; Leck H; Tang CY; Lee SJ; Cai Y; Ong RT; Koh TH; Tan TT; Kwa AL
Int J Antimicrob Agents; 2019 May; 53(5):657-662. PubMed ID: 30880229
[TBL] [Abstract][Full Text] [Related]
19. Association between carbapenem-resistant Enterobacteriaceae and death: A systematic review and meta-analysis.
Soontaros S; Leelakanok N
Am J Infect Control; 2019 Oct; 47(10):1200-1212. PubMed ID: 31072673
[TBL] [Abstract][Full Text] [Related]
20. The morbidity, mortality, and costs associated with Clostridium difficile infection.
Kwon JH; Olsen MA; Dubberke ER
Infect Dis Clin North Am; 2015 Mar; 29(1):123-34. PubMed ID: 25677706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
